// App-Quantinova.ai

TPS660 : Phase I dose-escalation trial of ONT-380 in combination with trastuzumab in participants with brain metastases from HER2+ breast cancer.

Researchers

Presenter

  • Otto Metzger-Filho

Principal Investigators

  • William Thomas Barry

  • Eric P. Winer

  • Nancy U. Lin

  • Ian E. Krop

  • W. Jerry Younger

  • Elizabeth S Lawler

Medical Centers

  • Massachusetts General Hospital, Boston, MA

  • Dana-Farber Cancer Institute, Boston, MA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Brain metastasis

  • Breast cancer

  • Solid malignancies

Biomarkers

  • Epidermal growth factor receptor

  • erb-b2 receptor tyrosine kinase 2

  • Hepatocyte growth factor receptor

Drug/Treatment

  • Trastuzumab

  • ARRY-380

  • ONT380

Outcome

  • Positive

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT01921335

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved